Company news
Kezar Life Sciences, Inc. news in 2024
Kezar Life Sciences, Inc.'s news releases, calls and decks from 2024, newest first.
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 11, 2024
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
October 27, 2024
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
October 16, 2024
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
October 16, 2024
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
October 3, 2024
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
September 29, 2024
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
July 9, 2024
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 5, 2024
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
March 13, 2024